Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients
Authors:
Open Access
- 17 September 2025
- journal article
- research article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 41 (1) , 2553052
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder in reproductive-aged women, often associated with obesity and dyslipidemia. Semaglutide, a GLP-1 receptor agonist (GLP-1 RA), improves glycemic control and weight, but its effects on PCOS remain unclear. This meta-analysis evaluates semaglutide's impact on BMI and blood lipids in PCOS patients. We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, WHO ICTRP, and gray literature sources for RCTs (2010-2025) comparing semaglutide vs. placebo/conventional treatment in PCOS patients. The outcomes included BMI, total cholesterol (TC), triglycerides (TG), LDL-C, and HDL-C. The data were analyzed using RevMan 5.4, with mean differences (MD) and 95% CIs were calculated. Heterogeneity was assessed via I². Eight RCTs (526 patients) were included. Semaglutide significantly reduced BMI (MD: -2.20 kg/m², 95% CI: -2.42 to -1.97, P < 0.001), TC (MD: -0.42 mmol/L, 95% CI: -0.46 to -0.39, P < 0.0001), TG (MD: -0.35 mmol/L, 95% CI: -0.38 to -0.32, P < 0.0001), and LDL-C (MD: -0.31 mmol/L, 95% CI: -0.35 to -0.27, P < 0.0001), but not HDL-C (P = 0.8524). Subgroup analysis showed greater efficacy at doses ≥ 1.0 mg/week and in patients with a baseline BMI > 28 kg/m². Overall evidence quality was moderate to low based on GRADE assessment. Semaglutide significantly improves BMI and lipid profiles in PCOS, particularly at higher doses, and in obese patients. Further long-term studies are needed to confirm safety and reproductive outcomes.Keywords
Funding Information
- Suzhou "Science, Education and Health Promotion" Youth Project (QNXM2024046)
This publication has 37 references indexed in Scilit:
- Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary SyndromeCurrent Obesity Reports, 2025
- Bridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?Naunyn-Schmiedeberg's Archives of Pharmacology, 2024
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or ObesityJAMA Internal Medicine, 2024
- The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trialsJournal of Diabetes and its Complications, 2024
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed SemaglutideJAMA Ophthalmology, 2024
- Gut Microbiota and Polycystic Ovary Syndrome (PCOS): Understanding the Pathogenesis and the Role of Probiotics as a Therapeutic StrategyProbiotics and Antimicrobial Proteins, 2024
- Pathophysiology and Nutritional Approaches in Polycystic Ovary Syndrome (PCOS): A Comprehensive ReviewCurrent Nutrition Reports, 2023
- As Ozempic’s Popularity Soars, Here’s What to Know About Semaglutide and Weight LossJAMA, 2023
- Semaglutide for the treatment of obesityTrends in Cardiovascular Medicine, 2023
- Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot studyDiabetes Research and Clinical Practice, 2021